stockrowAgenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow AGEN
Alert me
Agenus Inc. (AGEN) EV/Sales
As of 6 November 2026, Agenus Inc. (AGEN) trades at a EV/Sales of 3.2×. Over the past ten years it has ranged from 0.2× (August 2024) to 55.4× (June 2015); the current reading is higher than 42% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | 178.69% |
| FY2024 | 0.5× | (65.08%) |
| FY2023 | 1.4× | (71.07%) |
| FY2022 | 4.9× | 239.01% |
| FY2021 | 1.5× | (72.01%) |
| FY2020 | 5.2× | 58.70% |
| FY2019 | 3.3× | (45.01%) |
| FY2018 | 6.0× | (42.58%) |
| FY2017 | 10.4× | (42.86%) |
| FY2016 | 18.2× | 54.69% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 4.6× | 274.15% |
| Jun 2026 | 1.2× | 3.55% |
| Mar 2026 | 1.2× | (15.42%) |
| Dec 2025 | 1.4× | (3.34%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | −0.4× |
| SCTX Scribe Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| AGEN Agenus Inc. | 3.2× |
| PRLD Prelude Therapeutics Incorporated compare | 9.0× |
| XFOR X4 Pharmaceuticals, Inc. compare | 17.0× |
| BNTC Benitec Biopharma Limited compare | 3,500× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)